Who is sponsoring NCT02280850?

NCT02280850 is sponsored by Shaanxi Buchang Pharmaceutical Co., Ltd.

What condition does NCT02280850 study?

NCT02280850 studies Angina, Stable.

What drugs are being tested in NCT02280850?

Interventions: Guanxin Shutong Capsule, Placebo Capsule, nitroglycerine.

What is the status of NCT02280850?

NCT02280850 is currently UNKNOWN.

Last reviewed 2014-10-29 · How we verify

Efficacy and Safety Study of Guanxin Shutong Capsule to Treat Chronic Stable Angina: A Randomised, Double-blind, Placebo-controlled Clinical Trial

NCT02280850 Phase 4 UNKNOWN

Compared with placebo, assess of the efficacy and safety of Guanxin Shutong capsule to treat chronic stable angina (syndrome of blood stasis resistance), and the result will be used for the basis of later Ⅳ clinical trial.

Details

Lead sponsor	Shaanxi Buchang Pharmaceutical Co., Ltd
Phase	Phase 4
Status	UNKNOWN
Enrolment	300
Start date	2014-10
Completion	2015-10

Conditions

Angina, Stable

Interventions

Guanxin Shutong Capsule
Placebo Capsule
nitroglycerine

Primary outcomes

Therapeutic effect to Angina ( Average value of angina frequency) — 6 weeks
Record angina frequency per week. Record date is Start-up Stage 1st week, Start-up Stage 2st week, Interview Stage 1st week, Interview Stage 2st week, Interview Stage 3st week and Interview Stage 4st week (Toal of 6 times).
Exercise treadmill testing (ETT) — 4 weeks
ST-segment displacement in electrocardiogram: Observe ST-segment displacement of J point after 60ms, including the degree of ST-segment depression.

Countries

China